Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo OKs Drug Pricing Reform Package; 30% Cap Set for “Category I” Companies Allowed to Maintain Full Prices
December 21, 2017
-
BUSINESS GSK Japan Pres. Kikuchi to Quit after Only 9 Months in Office
December 20, 2017
-
BUSINESS Gilead Aiming to Develop World’s First NASH Treatment, Hoping for Approval in 2020
December 20, 2017
-
REGULATORY (Update) Japan to Shave 720 Billion Yen through FY2018 Drug Price Revision
December 19, 2017
-
REGULATORY Govt to Draw Up “Plan to Strengthen Drug Discovery,” Boosting Budgets to Improve R&D Environment
December 18, 2017
-
BUSINESS Partnerships Hold Key to Success, Acquisition Not Our Goal: Takeda R&D Head
December 15, 2017
-
REGULATORY Chuikyo Debate Intermitted as Members Fume at Political Arrangement, New PMP Plan Still Clears Panel with Strings Attached
December 14, 2017
-
REGULATORY Chuikyo Members Snub Possible Change to 14-Day Prescription Limit
December 13, 2017
-
BUSINESS Japan Drug Makers Driven by Overseas Sales, See Tepid Revenue at Home: Jiho Tally
December 12, 2017
-
REGULATORY MHLW Proposes Physician Fee for Proper Antibiotic Use in Children, Aims to Cut Unnecessary Use: Chuikyo
December 11, 2017
-
BUSINESS AbbVie Hopes Maviret Will Encourage Potential Hep C Patients to Get Treatment: Hepatitis Biz Head
December 11, 2017
-
REGULATORY Govt’s Modified PMP Plan: “1-Year Cutoff” Extended for 3 Years, 25% of Firms Could Now Maintain Full Prices
December 8, 2017
-
REGULATORY Easing of Proposed PMP Requirements Likely, Major Focus on “One-Year Cutoff” and “Category I” Scope
December 7, 2017
-
REGULATORY (Update) NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
-
REGULATORY NHI-Market Drug Price Gap at 9.1%, 7.1% Regular Price Cut Expected in FY2018
December 6, 2017
-
REGULATORY Novo’s Semaglutide Stumbles as Panel Puts a Hold on Japan Approval
December 5, 2017
-
REGULATORY CEFP Members Want Quicker Cuts for Off-Patent Drugs, Pricing Debate Enters Final Stretch
December 4, 2017
-
BUSINESS Ayumi Looks to Haul in Over 10 Billion Yen from 3 RA Biosimilars: President
December 1, 2017
-
REGULATORY Japan, US, Europe Trade Groups Forge United Front against Govt PMP Plan, Supportive of Negative List: Chuikyo
November 30, 2017
-
BUSINESS Japan’s 1st Rituxan Biosimilar to Arrive Soon, Sandoz Confident on Market Acquisition
November 29, 2017
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…